Risk factors
Alumis (ALMS) risk factors
Item 1A of every Alumis Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors79 risks17 new24 dropped22 reworded
Alumis integrated the ACELYRIN acquisition, adding $51.0 million in IPR&D intangible assets and scaling personnel to 224 employees.
Filed Mar 19, 2026 - FY2024 10-K risk factors86 risks
Alumis is a clinical-stage biopharmaceutical company focused on immunology, dominated by merger risks with Acelyrin and pipeline execution.
Filed Mar 19, 2025